Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

HistoSonics, the developer of the Edison histotripsy system and histotripsy therapy platform, announced a management-led majority ...

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.